Status:
ENROLLING_BY_INVITATION
SCRIPT: Sickle Cell Risk in Pregnancy Tool
Lead Sponsor:
Mount Sinai Hospital, Canada
Collaborating Sponsors:
Johns Hopkins University
Centre hospitalier de l'Université de Montréal (CHUM)
Conditions:
Sickle Cell Disease
Pregnancy, High Risk
Eligibility:
FEMALE
16-60 years
Brief Summary
Sickle Cell Disease (SCD), common in persons of Black ancestry, affects the shape of hemoglobin, the oxygen-carrying part of red blood cells (RBC). It is characterized by many complications, the most ...
Detailed Description
Sickle Cell Disease (SCD) is the most common haemoglobinopathy; predominantly affecting persons of African descent(1). In comparison to those without SCD, pregnant persons with SCD have a six-fold hig...
Eligibility Criteria
Inclusion
- Age \>16 years
- HbSS, HbSC, HbS/β0-thalassemia, HbS/β+-thalassemia confirmed on Hb electrophoresis, high performance liquid chromatography, capillary electrophoresis, or genetic testing
- Records of pregnancy care and birth at a participating centre
- Pregnancy continuing to at least 16+0 weeks' gestation (41,42)
Exclusion
- Inability to confirm SCD genotype
- Incomplete medical records.
Key Trial Info
Start Date :
September 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT06529042
Start Date
September 1 2024
End Date
December 1 2026
Last Update
November 27 2024
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Johns Hopkins University
Baltimore, Maryland, United States, 21218
2
Providence Health Care
Vancouver, British Columbia, Canada, V5Z 1M9
3
Centre hospitalier de l'Université de Montréal
Montreal, Quebec, Canada, H2X 0C1